The clinical benefits of zanamivir in influenza

International Journal of Pharmaceutical Medicine

Volumn 13, Issue 6, 1999, Pages 333-335

  Snell, N J C ^a  

^a Bayer Pharma   (United Kingdom)

Author keywords

Influenza; National Institute for Clinical Excellence (NICE); Zanamivir

Indexed keywords

ZANAMIVIR;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; META ANALYSIS; NATIONAL HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

EID: 0033401234     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. 1. Oxford J, Lambkin R. Targeting influenza virus neuraminidase - a new strategy for antiviral therapy. Drug DiscoveryToday 1998; 3: 448-456.
2. 2. Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir - a review of clinical safety. Drug Safely 1999; 21: 267-281.
3. 3. Cass L, Brown J, Pickford M et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36 (supp 1): 21-31.
4. 4. Dunn C, Goa K. Zanamivir - a review of its use in influenza. Drugs 1999; 58: 761-784.
5. 5. Hayden F, Treanor J, Betts R et al. Safety and efficacy of the neuraminidase inhibitor GG 167 in experimental human influenza. JAMA 1996; 275: 295-9.
6. 6. Hayden F, Osterhaus A, Treanor J et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New Engl J Med 1997; 337: 874-80.
7. 7. Monto A, Fleming D, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 245-61.
8. 8. Matsumoto K, Ogawa N, Nerome K et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antiviral Ther 1999; 4: 61-8.
9. 9. The MIST study group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
10. 10. Monto A, Robinson D, Herlocher M, Hinson J, Elliott M, Crisp A. Zanamivir in the prevention of influenza among healthy adults - a randomised controlled trial. JAMA 1999; 282: 31-35.
11. 11. Schilling M, Povinelli L, Krause P et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998; 16: 1771-4.
12. 12. Ellis S. Some unanswered questions about NICE. J Roy Soc Med 1999; 92: 538-539.
13. 13. Hayden F, Gubareva L, Klein T et al. Inhaled zanamivir for preventing transmission of influenza in families. 39th Annual ICAAC, San Francisco, 1999 (addendum); Abstract LB-2.
14. 14. Kaiser L, Hayden F, Hammond J, Keene O. Efficacy of inhaled zanamivir in reducing complications ad antibiotic use in influenza - results of phase II and III clinical studies. 39th Annual ICAAC, San Francisco, 1999; Abstract 1903.
15. 15. Lalezari J, Elliot M, Keene O. The efficacy and safety of inhaled zanamivir in the treatment of influenza A and B in 'high-risk' individuals - results of phase II and III clinical studies. 39th Annual ICAAC, San Francisco, 1999; Abstract 282.
16. 16. Nicholson K, Ward P, Kinersley N. Oral GS 4104 in the treatment of influenza in adults is effective and reduces influenza-related complications and need for antibiotic treatment. J Antimicrob Chemother 1999; 44 (suppl A): 13-14.
17. 17. Mendel D, Sidwell R. Influenza virus resistance to neuraminidase inhibitors. Drug Resistance Updates 1998; 1: 184-189.
18. 18. Gubareva L, Matrosovich M, Brenner M, Bethell R, Webster R. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257-1262.